Esta página aún no está traducida al español y se muestra en inglés. Estamos trabajando en su traducción.

Esta referencia está disponible actualmente en inglés. La versión en español está en preparación.

IV Nutrient Formulations: What the Trials and the Agencies Report

Por Benn Bluestein-Veyra, M.Sc. en Química Orgánica · Actualizado el 9 de noviembre de 2026

ExaVeyra Sciences es un proveedor B2B con sede en Miami que suministra exosomas para uso estético tópico a clínicas con licencia, y trabaja con una farmacia de preparados compuestos 503A que prepara formulaciones para prescriptores con licencia según prescripciones individuales.

Qué cubre esta página, quién puede comprar a ExaVeyra, y qué se suministra
PreguntaRespuesta
Qué cubre esta páginaIV vitamin formulation evidence: the placebo-controlled Myers cocktail pilot, vitamin C pharmacokinetics by route, NIH fact sheets and FDA's compounding frame.
Quién puede hacer pedidosClínicas y profesionales con licencia profesional activa y NPI verificados por ExaVeyra. Los pedidos de exosomas requieren además un reconocimiento firmado de uso profesional.
Qué se envía y cómoLas formulaciones compuestas las prepara y dispensa nuestra farmacia asociada 503A según una prescripción individual del profesional con licencia, y se envían desde la farmacia. Las sustancias controladas las dispensa la farmacia con su propio registro de la DEA.

The first controlled trial of the Myers cocktail, a 2009 randomized, double-blind, placebo-controlled pilot in 34 adults with fibromyalgia, reported that "no statistically significant differences were seen between groups, in any outcome measure" at eight and sixteen weeks, and its authors concluded that "the efficacy of IVMT [intravenous micronutrient therapy] for fibromyalgia, relative to placebo, is as yet uncertain."[1] The pharmacokinetic work from the National Institutes of Health shows a route effect: oral vitamin C produces plasma concentrations that are "tightly controlled", and only intravenous administration produces concentrations above that ceiling.[2][3] A 2023 review in Drug and Therapeutics Bulletin summarized the field as "a lack of high-quality evidence to suggest that high-dose vitamin infusions are necessary or offer any health benefit in the absence of a specific vitamin deficiency or medical condition."[4]

This page reports what the trials, the approved labels, the NIH Office of Dietary Supplements and NCCIH state about intravenous vitamin and mineral formulations, and what FDA and section 503A require of anyone who prepares them as sterile compounded drugs.[5][6][7]

The placebo-controlled Myers cocktail pilot reported no statistically significant difference from placebo

Ali and colleagues at Yale randomized 34 adults meeting American College of Rheumatology criteria for fibromyalgia to weekly infusions of the Myers cocktail or of lactated Ringer's solution for eight weeks, with the Tender Point Index as the primary outcome.[1] Both groups improved from baseline, and the authors attributed the absence of statistically significant between-group differences in part to "the high placebo response and the small sample size"; a single minor adverse event occurred in one treated subject, and the trial "established the safety and feasibility" of the approach while leaving efficacy undetermined.[1]

The Drug and Therapeutics Bulletin review placed the formulation in context: intravenous vitamins "are used for a few serious medical conditions (eg, malabsorption syndromes with severe vitamin depletion, Wernicke's encephalopathy or critical illness)", while infusions promoted to reduce stress, increase energy or boost immunity rest on a claim about faster absorption, and "there may be harms from taking high (non-physiological) quantities of some vitamins and minerals."[4] Licensed injectable vitamins that "are prescription-only medicines," it added, "should not be advertised to the public and should only be supplied and administered by appropriately qualified healthcare professionals."[4]

Vitamin C pharmacokinetics differ by route, and the trials of high concentrations enrolled patients under specialist care

Padayatty and colleagues at the NIH Clinical Center gave oral and intravenous vitamin C to healthy volunteers and found that "oral vitamin C produces plasma concentrations that are tightly controlled" while "only intravenous administration of vitamin C produces high plasma and urine concentrations."[2] Levine's 2011 review reported that with amounts found in foods plasma concentrations do not exceed 100 micromoles per liter, that supplementation near the maximally tolerated amount keeps plasma below 250 micromoles per liter, and that intravenous ascorbate bypasses this control "until excess ascorbate is eliminated by glomerular filtration and renal excretion."[3] The ODS fact sheet records the same physiology: "the body tightly controls tissue and plasma concentrations of vitamin C."[8]

The clinical trials of pharmacologic intravenous vitamin C have enrolled patients under specialist care. In an uncontrolled phase I to II trial in 14 patients with advanced cancer receiving chemotherapy, Hoffer and colleagues reported the infusions "safe and generally well tolerated" and the study one that "neither proves nor disproves IVC's value in cancer therapy."[9] In the LOVIT trial, 872 adults with sepsis on vasopressors were randomized to intravenous vitamin C or placebo for up to four days; death or persistent organ dysfunction at 28 days occurred in 44.5 percent of the vitamin C group against 38.5 percent with placebo (risk ratio 1.21), with one severe hypoglycemic episode and one serious anaphylaxis event on vitamin C.[10] CITRIS-ALI, a 167-patient trial in sepsis with acute respiratory distress syndrome, found no significant difference in organ failure scores or inflammatory markers.[11] Carr and colleagues found hypovitaminosis C in 44 critically ill patients "despite receiving recommended intakes via enteral and/or parenteral nutritional therapy."[12]

Padayatty's 2010 survey of complementary medicine practitioners found intravenous vitamin C "in unexpectedly wide use" and 101 side effects, mostly minor, among 9,328 patients with data; the authors' review of published cases documented "serious adverse events, including 2 deaths in patients known to be at risk", and they placed the known complications "in those with renal impairment or glucose 6 phosphate dehydrogenase deficiency."[13]

The approved intravenous vitamin C product is labeled for scurvy, with oxalate and hemolysis warnings

ASCOR (ascorbic acid injection), approved under NDA 209112 on 2 October 2017, is "indicated for the short term (up to 1 week) treatment of scurvy in adult and pediatric patients age 5 months and older for whom oral administration is not possible, insufficient or contraindicated", and "is not indicated for treatment of vitamin C deficiency that is not associated with signs and symptoms of scurvy."[14] Its warnings record that ascorbic acid "has been associated with development of acute or chronic oxalate nephropathy following prolonged use of high doses of ascorbic acid infusion", that patients with glucose-6-phosphate dehydrogenase deficiency "are at risk of severe hemolysis", and that it "may interfere with laboratory tests based on oxidation-reduction reactions, including blood and urine glucose testing"; the most common adverse reactions are pain and swelling at the infusion site.[14] The product is a Pharmacy Bulk Package to be used "only in a suitable ISO Class 5 work area such as a laminar flow hood" and diluted to an isotonic infusion.[14]

What the Cochrane review and the ODS fact sheet state about vitamin B12 by injection and by mouth

The ODS fact sheet explains that vitamin B12 must bind intrinsic factor before absorption in the distal ileum, and that "certain forms of vitamin B12 are available as prescription medications" that "are generally used to treat vitamin B12 deficiency."[15] It records that vitamin B12 "does not have a tolerable upper intake level because it is generally considered to be safe, even at high doses", and that supplementation "does not appear to improve athletic performance or endurance in people who have sufficient vitamin B12 status."[15]

The 2018 Cochrane review of oral against intramuscular vitamin B12 for deficiency included three randomized trials with 153 participants followed for three to four months.[16] It reported "no clinically relevant difference in vitamin B12 levels" between the routes in two trials, graded the evidence as low quality, and noted lower costs with the oral route in one trial; no trial reported on clinical signs and symptoms of deficiency.[16]

Magnesium status is hard to measure, and the intravenous trials are in emergency departments

The ODS fact sheet states that "serum levels do not accurately reflect total body magnesium levels or concentrations in specific tissues", that symptomatic deficiency "is uncommon in healthy people", and that "very high doses of magnesium can lead to magnesium toxicity, which can cause hypotension, vomiting, difficulty breathing, irregular heartbeat, cardiac arrest, and other signs and symptoms", with "a few cases of fatal hypermagnesemia" reported.[17] A 2019 systematic review of intravenous magnesium sulfate for acute non-traumatic headache in emergency departments found seven randomized trials with 545 participants, could not pool them, and concluded that "we cannot draw a firm conclusion on the efficacy or benefit of intravenous magnesium sulfate."[18]

NCCIH and ODS frame nutrient needs around diet, and the IV hydration spa studies record the gap between claims and sources

NCCIH states that the Dietary Guidelines for Americans recommend meeting nutritional requirements "through a healthy eating pattern that includes nutrient-dense foods", and that "health care providers may recommend supplements for people with certain medical conditions."[7] Each ODS fact sheet closes the same way: nutritional needs "should be met primarily through the diet."[8][15][17]

A 2025 JAMA Internal Medicine study reviewed state policies and 255 IV hydration spa websites and ran a secret shopper study of 87 facilities.[19] Thirty-two states had issued some guidance but only four addressed governance, prescriber credentials, dispensing and compounding together; magnesium (57.3 percent) and glutathione (53.7 percent) were the most common add-ins; every website made claims of benefit while two (0.8 percent) cited a source; and 27.6 percent of shopped facilities required consultation with a licensed professional.[19] A 2025 case report described Stevens-Johnson syndrome in a woman after an infusion of glutathione, vitamin C and vitamin D at a hydration clinic, and asked clinicians to inquire about "hydration and wellness center infusions" when seeking a cause.[20]

FDA actions reach IV wellness businesses through insanitary conditions and ingredient grade

FDA's warning letter of 18 April 2022 to Age Management Institute Santa Barbara followed a 2021 inspection of a practice that produced "drug products for IV therapy."[21] The investigator found that the facility "lacked a certified ISO 5 classified area for sterile compounding", that a hood "had a visibly dirty filter installed", that the mixing room floor was partly carpeted, and that the firm "distributed drug products that were prepared using expired components."[21] FDA stated that the insanitary conditions provision "applies regardless of whether drug products you compound meet the conditions of section 503A"; the firm voluntarily ceased IV therapy production.[21]

On 27 August 2026 FDA reported "at least 30 patients who experienced adverse events following the administration of intravenous (IV) glutathione alone or in combination with other ingredients", traced to one lot "labeled as dietary supplement grade", with two Texas pharmacies recalling for elevated endotoxin and events including fever, chills, signs of shock and hospitalization.[22] The agency wrote that compounders "should not use dietary supplement grade ingredients when making injectable drugs" and that "health care professionals should check with their compounders regarding the source of the glutathione used to make injectable drugs for their patients."[22] FDA's compounding laws page records the background: in 2012 contaminated compounded drugs "led to more than 750 cases of infection and more than 60 deaths of patients in 20 states", and Congress passed the Drug Quality and Security Act in 2013.[23] Gudeman and colleagues wrote in 2013 that "compounded sterile preparations pose the additional risk of microbial contamination to patients."[24]

Sections 503A and 503B set the frame for who may prepare a sterile intravenous nutrient formulation and for whom

Section 503A exempts a compounded drug from approval, adequate directions for use and current good manufacturing practice only "if the drug product is compounded for an identified individual patient based on the receipt of a valid prescription order", by "(A) a licensed pharmacist in a State licensed pharmacy or a Federal facility, or (B) a licensed physician."[5] Bulk drug substances must "comply with the standards of an applicable United States Pharmacopoeia or National Formulary monograph, if a monograph exists, and the United States Pharmacopoeia chapter on pharmacy compounding", come from a registered establishment and be "accompanied by valid certificates of analysis for each bulk drug substance"; and the compounder may not compound "regularly or in inordinate amounts" drugs that are "essentially copies of a commercially available drug product."[5]

FDA's Q&A explains that state boards of pharmacy "have primary responsibility for the day-to-day oversight" of 503A pharmacies, that 503A drugs are not subject to CGMP although "other federal law applies, including provisions regarding insanitary conditions", and that "compounded drugs should only be used in patients whose medical needs cannot be met by an FDA-approved drug."[6] Section 503B outsourcing facilities are subject to CGMP, are inspected by FDA on a risk-based schedule, and "may distribute compounded drugs either pursuant to a patient-specific prescription or in response to an order from a health care provider, such as a hospital, that is not for an identified individual patient (e.g., for office stock)."[23]

NeedRoute the sources describeConditions stated
An intravenous vitamin preparation for one named patientA 503A pharmacy on a patient-specific prescriptionLicensed pharmacist or physician; USP monograph and compounding chapter; registered API source with a certificate of analysis
Stock held in the office for infusion as neededA 503B outsourcing facility, or an FDA-approved productCGMP, FDA registration and inspection, adverse event reporting
Intravenous vitamin CASCOR (NDA 209112), or a 503A preparation where the prescriber documents a difference for the patientLabel indication is short-term scurvy where oral use is not possible; oxalate and hemolysis warnings; ISO Class 5 admixture
Preparation in the practice itselfA licensed physician under 503AThe insanitary conditions provision applies regardless of 503A status

The table draws on section 503A, FDA's compounding laws page and the ASCOR label.[5][14][23]

Records a practice would hold under the statute, FDA communications and the approved labels

The statute, FDA's communications and the approved labels describe a short set of records for a practice that orders or administers intravenous nutrient formulations.[5][14][22]

  • A patient-specific prescription for any 503A preparation, and a 503B or approved-product source for anything held as office stock.
  • The pharmacy's certificate of analysis for each bulk ingredient, with the upstream manufacturer identified, as FDA's 2026 glutathione alert asked suppliers to state.
  • For vitamin C, the renal and glucose-6-phosphate dehydrogenase considerations the ASCOR label and the 2010 survey both name.
  • Where an approved product with the same ingredient and route exists, the prescriber's documented reason for a compounded preparation, since section 503A bars compounding, regularly or in inordinate amounts, of drugs that are essentially copies of a commercially available drug product.

ExaVeyra's injectable vitamin and nutrient preparations reach a practice through its licensed 503A pharmacy partner on a patient-specific prescription, with a certificate of analysis for each lot available on request. Whether a given patient receives an intravenous formulation, an approved product or an oral form, and how the patient is assessed and monitored, are decisions for the prescribing practitioner, and section 503A ties each preparation to a valid prescription for an identified individual patient.[5]

This article summarizes publicly available federal regulation for licensed practitioner education. It is not legal advice, medical advice, or regulatory guidance, and it does not establish that any particular product or practice is compliant. Confirm current federal and state obligations with qualified counsel.

Referencias comentadas

Numeradas en el orden en que se citan en el texto. Cada fuente lleva una nota sobre lo que respalda en esta página; los artículos revisados por pares se listan con revista, volumen, número y páginas, y las fuentes primarias son regulaciones, documentos de agencias, guías y declaraciones de posición.

  1. 1.Peer-reviewedAli A, Njike VY, Northrup V, Sabina AB, Williams AL, Liberti LS, Perlman AI, Adelson H, Katz DL. Intravenous micronutrient therapy (Myers' Cocktail) for fibromyalgia: a placebo-controlled pilot study. Journal of Alternative and Complementary Medicine. 2009;15(3):247-257. https://pubmed.ncbi.nlm.nih.gov/19250003/Annotation: The first randomized, double-blind, placebo-controlled pilot of the Myers cocktail: weekly infusions against lactated Ringer's for eight weeks in 34 adults with fibromyalgia, no between-group difference in any outcome, one minor adverse event.
  2. 2.Peer-reviewedPadayatty SJ, Sun H, Wang Y, Riordan HD, Hewitt SM, Katz A, Wesley RA, Levine M. Vitamin C pharmacokinetics: implications for oral and intravenous use. Annals of Internal Medicine. 2004;140(7):533-537. https://pubmed.ncbi.nlm.nih.gov/15068981/Annotation: Oral and intravenous vitamin C in healthy volunteers with pharmacokinetic modeling: oral concentrations are tightly controlled and only intravenous administration produces high plasma and urine concentrations.
  3. 3.Peer-reviewedLevine M, Padayatty SJ, Espey MG. Vitamin C: a concentration-function approach yields pharmacology and therapeutic discoveries. Advances in Nutrition. 2011;2(2):78-88. https://pubmed.ncbi.nlm.nih.gov/22332036/Annotation: The NIH account of the three mechanisms that cap oral vitamin C concentrations, the plasma ceilings from food and supplements, and how intravenous ascorbate bypasses them until renal excretion.
  4. 4.Peer-reviewedDrug and Therapeutics Bulletin. Intravenous vitamin injections: where is the evidence? Drug and Therapeutics Bulletin. 2023;61(10):151-155. https://pubmed.ncbi.nlm.nih.gov/37640530/Annotation: The independent review's statements that intravenous vitamins have a few serious medical indications, that high-dose infusions lack high-quality evidence of benefit absent deficiency, that harms are possible, and that licensed injectable vitamins are prescription-only medicines.
  5. 5.Regulatory21 U.S.C. 353a, Pharmacy compounding (United States Code, 2024 edition, GPO). Accessed 8 November 2026. https://www.govinfo.gov/content/pkg/USCODE-2024-title21/html/USCODE-2024-title21-chap9-subchapV-partA-sec353a.htm
  6. 6.RegulatoryFDA, Compounding and the FDA: Questions and Answers (content current 16 September 2025). Accessed 8 November 2026. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
  7. 7.Official sourceNational Center for Complementary and Integrative Health, Vitamins and Minerals (last updated July 2023). Accessed 8 November 2026. https://www.nccih.nih.gov/health/vitamins-and-minerals
  8. 8.Official sourceNIH Office of Dietary Supplements, Vitamin C: Fact Sheet for Health Professionals (updated 31 July 2025). Accessed 8 November 2026. https://ods.od.nih.gov/factsheets/VitaminC-HealthProfessional/
  9. 9.Peer-reviewedHoffer LJ, Robitaille L, Zakarian R, Melnychuk D, Kavan P, Agulnik J, Cohen V, Small D, Miller WH Jr. High-dose intravenous vitamin C combined with cytotoxic chemotherapy in patients with advanced cancer: a phase I-II clinical trial. PLoS One. 2015;10(4):e0120228. https://pubmed.ncbi.nlm.nih.gov/25848948/Annotation: Phase I to II safety and pharmacokinetic trial in 14 patients with advanced cancer: infusions safe and generally well tolerated, transient adverse events, and the authors' statement that the study neither proves nor disproves value.
  10. 10.Peer-reviewedLamontagne F, Masse MH, Menard J, Sprague S, Pinto R, Heyland DK, Cook DJ, Battista MC, et al. (LOVIT Investigators). Intravenous Vitamin C in Adults with Sepsis in the Intensive Care Unit. New England Journal of Medicine. 2022;386(25):2387-2398. https://pubmed.ncbi.nlm.nih.gov/35704292/Annotation: The LOVIT trial: 872 adults with sepsis on vasopressors randomized to intravenous vitamin C or placebo; higher risk of death or persistent organ dysfunction at 28 days with vitamin C (44.5 against 38.5 percent), one severe hypoglycemia and one serious anaphylaxis event.
  11. 11.Peer-reviewedFowler AA 3rd, Truwit JD, Hite RD, Morris PE, DeWilde C, Priday A, Fisher B, Thacker LR 2nd, et al. Effect of Vitamin C Infusion on Organ Failure and Biomarkers of Inflammation and Vascular Injury in Patients With Sepsis and Severe Acute Respiratory Failure: The CITRIS-ALI Randomized Clinical Trial. JAMA. 2019;322(13):1261-1270. https://pubmed.ncbi.nlm.nih.gov/31573637/Annotation: Multicenter double-blind trial in 167 patients with sepsis and acute respiratory distress syndrome: no significant difference from placebo in organ failure score, C-reactive protein or thrombomodulin after a four-day infusion.
  12. 12.Peer-reviewedCarr AC, Rosengrave PC, Bayer S, Chambers S, Mehrtens J, Shaw GM. Hypovitaminosis C and vitamin C deficiency in critically ill patients despite recommended enteral and parenteral intakes. Critical Care. 2017;21(1):300. https://pubmed.ncbi.nlm.nih.gov/29228951/Annotation: Plasma vitamin C in 44 critically ill patients over four days: hypovitaminosis C overall and deficiency in one third despite recommended enteral or parenteral intakes, lower in septic shock; the population context for the sepsis trials.
  13. 13.Peer-reviewedPadayatty SJ, Sun AY, Chen Q, Espey MG, Drisko J, Levine M. Vitamin C: intravenous use by complementary and alternative medicine practitioners and adverse effects. PLoS One. 2010;5(7):e11414. https://pubmed.ncbi.nlm.nih.gov/20628650/Annotation: Practitioner survey and manufacturer sales data: wide use of intravenous vitamin C by complementary practitioners, 101 side effects among 9,328 patients with data, published deaths in at-risk patients, and the renal and G6PD risks.
  14. 14.Official sourceDailyMed, ASCOR (ascorbic acid) injection, McGuff Pharmaceuticals, Inc. (prescribing information, NDA 209112). Accessed 8 November 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=388aad52-fc01-4784-9791-1dbc80c69306
  15. 15.Official sourceNIH Office of Dietary Supplements, Vitamin B12: Fact Sheet for Health Professionals (updated 2 July 2025). Accessed 8 November 2026. https://ods.od.nih.gov/factsheets/VitaminB12-HealthProfessional/
  16. 16.Peer-reviewedWang H, Li L, Qin LL, Song Y, Vidal-Alaball J, Liu TH. Oral vitamin B12 versus intramuscular vitamin B12 for vitamin B12 deficiency. Cochrane Database of Systematic Reviews. 2018;3(3):CD004655. https://pubmed.ncbi.nlm.nih.gov/29543316/Annotation: Three randomized trials, 153 participants with vitamin B12 deficiency: no clinically relevant difference in serum B12 between oral and intramuscular treatment in two trials, low-quality evidence, lower costs with the oral route in one trial.
  17. 17.Official sourceNIH Office of Dietary Supplements, Magnesium: Fact Sheet for Health Professionals (updated 6 January 2026). Accessed 8 November 2026. https://ods.od.nih.gov/factsheets/Magnesium-HealthProfessional/
  18. 18.Peer-reviewedMiller AC, K Pfeffer B, Lawson MR, Sewell KA, King AR, Zehtabchi S. Intravenous Magnesium Sulfate to Treat Acute Headaches in the Emergency Department: A Systematic Review. Headache. 2019;59(10):1674-1686. https://pubmed.ncbi.nlm.nih.gov/31566727/Annotation: Seven randomized trials with 545 emergency department patients with acute non-traumatic headache: meta-analysis not performed for heterogeneity, no firm conclusion on efficacy, potential benefit in pain control beyond one hour.
  19. 19.Peer-reviewedSivakumar A, Forman HP, Wang I, Lurie P, Ross JS. State Policies and Facility Practices of IV Hydration Spas in the US. JAMA Internal Medicine. 2025;185(12):1455-1461. https://pubmed.ncbi.nlm.nih.gov/41051745/Annotation: Policy review of 50 states and DC, 255 IV hydration spa websites and 87 secret-shopper visits: 32 states with some guidance, four addressing all four oversight areas, magnesium and glutathione the commonest add-ins, 0.8 percent of sites citing a source for claims.
  20. 20.Peer-reviewedJohnson JS, Jarvis NR, Martinez AM, Dvorak JE. Intravenous Glutathione and Vitamin Supplementation Causing Stevens-Johnson Syndrome: A Case Report. Journal of Burn Care and Research. 2025;46(3):652-655. https://pubmed.ncbi.nlm.nih.gov/40057759/Annotation: Stevens-Johnson syndrome and toxic epidermal necrolysis in a 33-year-old woman after an IV infusion of glutathione, vitamin C and vitamin D at a hydration clinic; the authors' call to ask about wellness center infusions when seeking a cause.
  21. 21.RegulatoryFDA, Warning Letter to Age Management Institute Santa Barbara, MARCS-CMS 625261 (18 April 2022). Accessed 8 November 2026. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/age-management-institute-santa-barbara-625261-04182022
  22. 22.RegulatoryFDA, FDA reminds compounders not to use dietary supplement grade glutathione for injectables (compounding risk alert, 27 August 2026). Accessed 8 November 2026. https://www.fda.gov/drugs/human-drug-compounding/fda-reminds-compounders-not-use-dietary-supplement-grade-glutathione-injectables
  23. 23.RegulatoryFDA, Human Drug Compounding Laws (Drug Quality and Security Act, sections 503A and 503B; content current 17 December 2024). Accessed 8 November 2026. https://www.fda.gov/drugs/human-drug-compounding/human-drug-compounding-laws
  24. 24.Peer-reviewedGudeman J, Jozwiakowski M, Chollet J, Randell M. Potential risks of pharmacy compounding. Drugs in R&D. 2013;13(1):1-8. https://pubmed.ncbi.nlm.nih.gov/23526368/Annotation: The review of compounding risk after the 2012 meningitis outbreak: compounded sterile preparations carry microbial contamination risk, and independent testing finds compounded drugs failing specifications at a higher rate than approved drugs.

Cite this page

ExaVeyra Sciences Editorial Team. IV Nutrient Formulations: What Trials Report. ExaVeyra Sciences; 9 November 2026. Available from: https://exaveyra.com/science/compounds/iv-nutrient-formulations-trials. Accessed [date accessed].

Recursos exclusivos para miembros de ExaVeyra

Para prácticas verificadas y aprobadasReservado para profesionales clínicos

Bóveda de investigación

Literatura revisada por pares seleccionada para cada compuesto del catálogo, con un resumen imprimible de dos minutos, la evidencia de un vistazo y los artículos por los que empezar.

  • 266 artículos revisados por pares, cada uno con su enlace DOI o PubMed
  • 8 áreas de investigación
  • 128 revisiones sistemáticas, metaanálisis y ensayos aleatorizados
  • 18 compuestos con un resumen de dos minutos

El registro toma unos dos minutos. El acceso se habilita tras la verificación del NPI y una revisión de nuestro equipo. No se piden datos de pago.

Cada resumen empieza por los diseños de estudio más sólidos y luego los más recientes.

Preguntas frecuentes

What did the Myers cocktail trial report?
The randomized, double-blind, placebo-controlled pilot published in 2009, which its authors described as the first controlled study, enrolled 34 adults with fibromyalgia at Yale and compared weekly infusions of the Myers cocktail with lactated Ringer's solution for eight weeks. Both groups improved from baseline, no statistically significant difference between groups was seen in any outcome measure at eight or sixteen weeks, one minor adverse event occurred in the treatment arm, and the authors described efficacy relative to placebo as uncertain.
Does intravenous vitamin C produce different plasma concentrations from oral vitamin C?
Yes. The NIH pharmacokinetic studies in healthy volunteers found that oral vitamin C produces tightly controlled plasma concentrations through limited absorption, tissue saturation and renal reabsorption, and that only intravenous administration produces concentrations above that ceiling. The trials of those higher concentrations enrolled patients under specialist care: an uncontrolled 14-patient phase I to II trial with chemotherapy that neither proved nor disproved benefit, and two placebo-controlled sepsis trials, one of which found a higher rate of death or persistent organ dysfunction with vitamin C than with placebo.
What is the FDA-approved intravenous vitamin C product labeled for?
ASCOR (ascorbic acid injection), NDA 209112 approved in October 2017, is labeled for short-term treatment of scurvy where oral administration is not possible, insufficient or contraindicated, and its label states that it is not indicated for vitamin C deficiency without signs and symptoms of scurvy. The label warns of oxalate nephropathy with prolonged high-dose infusion, severe hemolysis in glucose-6-phosphate dehydrogenase deficiency and interference with glucose tests, and requires preparation in an ISO Class 5 area as a pharmacy bulk package.
How do injected and oral vitamin B12 compare in the Cochrane review?
The 2018 Cochrane review of three randomized trials with 153 participants with vitamin B12 deficiency reported no clinically relevant difference in serum B12 between oral and intramuscular treatment in two trials, graded the evidence as low quality, and noted lower costs with the oral route in one trial. The ODS fact sheet states that prescription forms of B12 are generally used to treat deficiency and that supplementation does not appear to improve performance or endurance in people with sufficient status.
What has FDA said to IV hydration and wellness businesses?
In an April 2022 warning letter to a Santa Barbara practice that produced "drug products for IV therapy," FDA described a missing certified ISO 5 area, a dirty hood filter, carpet in the mixing room, components standing in refrigerator condensate and expired ingredients, and stated that the insanitary conditions provision applies regardless of whether a compounder meets section 503A. In August 2026 FDA reported at least 30 adverse events from IV glutathione compounded from dietary supplement grade material and asked health care professionals to check the ingredient source with their compounders.
Can a clinic hold intravenous vitamin preparations as office stock?
Section 503A covers compounding for an identified individual patient on a valid prescription, so a 503A pharmacy supplies against patient-specific prescriptions. FDA states that 503B outsourcing facilities, which operate under CGMP and FDA inspection, may distribute compounded drugs in response to a health care provider order that is not for an identified patient, such as office stock; FDA-approved products, such as ASCOR, are the other route to stock.

Esta página se ofrece únicamente con fines informativos. No constituye consejo médico, no está destinada a diagnosticar, tratar, curar ni prevenir ninguna enfermedad, y no sustituye el criterio de un profesional con licencia. Consulte a un profesional de la salud antes de actuar sobre cualquier cosa que aquí se afirme. ExaVeyra Sciences es un proveedor y no participa en ningún diagnóstico, decisión de tratamiento ni plan de atención. Estas referencias informan lo que los ensayos, las revisiones, las etiquetas de los productos y las comunicaciones de la FDA establecen sobre los compuestos que prepara una farmacia 503A asociada, con fines de formación profesional, y no hacen ninguna afirmación sobre la idoneidad de ningún producto para ningún paciente. Cuando esta página trata un producto aprobado por la FDA, rige el etiquetado aprobado y nada de lo aquí expuesto lo modifica. Las preparaciones compuestas son una clase de producto distinta: no son productos farmacéuticos terminados aprobados por la FDA, se preparan bajo la sección 503A de la Ley Federal de Alimentos, Medicamentos y Cosméticos contra una prescripción específica para un paciente, y son productos de prescripción suministrados únicamente a profesionales con licencia. Los ingredientes cosméticos que se tratan aquí se describen dentro del marco regulatorio cosmético y no son medicamentos. La decisión de prescribir corresponde al profesional con licencia. Leer el aviso completo

Solo de referencia. No constituye asesoramiento legal ni médico.

El contenido de estas guías se ofrece únicamente con fines informativos generales. No constituye asesoramiento legal, médico ni regulatorio, y no debe interpretarse como una confirmación de que determinado producto o determinada práctica cumple con la normativa aplicable. Los requisitos regulatorios varían según el estado y dependen de las circunstancias de cada práctica. Cada profesional debe consultar a su propio asesor legal y a las juntas estatales de licenciamiento aplicables antes de actuar sobre cualquier cosa que aquí se afirme.

Leer el aviso completo